MiNK Therapeutics (INKT) Projected to Post Earnings on Tuesday

MiNK Therapeutics (NASDAQ:INKT) will likely be announcing its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 18, 2026 at 12:30 PM ET.

MiNK Therapeutics Trading Up 1.7%

NASDAQ:INKT opened at $10.45 on Tuesday. MiNK Therapeutics has a 1-year low of $6.34 and a 1-year high of $76.00. The stock has a market cap of $49.01 million, a P/E ratio of -3.45 and a beta of 0.35. The stock’s 50-day moving average is $11.54 and its 200-day moving average is $12.78.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MiNK Therapeutics stock. Geode Capital Management LLC boosted its holdings in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 14,247 shares of the company’s stock after purchasing an additional 1,441 shares during the quarter. Geode Capital Management LLC owned about 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent quarter. 2.87% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 19th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, MiNK Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $35.00.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.